Charles River Laboratories International reported first-quarter revenue of $995.83 million, surpassing Wall Street estimates but highlighting ongoing financial difficulties, including a year-over-year organic revenue decline of 1.5%. The adjusted earnings per share (EPS) fell 12% to $2.06, with management maintaining a cautious outlook for 2026, forecasting further revenue drops. Despite a recent $200 million stock buyback and a positive one-year return, the company faces significant long-term concerns following a 43.4% decline over five years.
“Charles River Laboratories International · reported · first-quarter revenue · $996 million”
“Charles River Laboratories International · reaffirmed · full-year 2026 guidance · organic revenue down 0.5% to 1.5%”
“Charles River Laboratories International · said · margins are impacted by NHP costs · true”
“Charles River Laboratories · has · Zacks Rank · #3 (Hold)”
“Charles River Laboratories · has · forward P/E ratio · 16.57”
“Charles River Laboratories · has · PEG ratio · 2.20”
“Charles River Laboratories · has · P/B ratio · 3.04”
“Charles River Laboratories · holds · Value grade · C”
“Charles River Laboratories International · current market price · US$181.68”
“Charles River Laboratories International · 1 year return · 28.5%”
“Charles River Laboratories International · 5 year return · down 43.4%”
“Charles River Laboratories International · year to date return · down 10.2%”